DOCSLIB.ORG

Effectiveness of Acid Suppressants and Other Mucoprotective Agents In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

www.nature.com/scientificreports OPEN Efectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult Received: 27 April 2018 Accepted: 31 July 2019 gastrointestinal bleeding in Published: xx xx xxxx nonsteroidal anti-infammatory drug users Tae Jun Kim1, Eun Ran Kim1, Sung Noh Hong 1, Young-Ho Kim1, Yeong Chan Lee 2, Hye Seung Kim 3, Kyunga Kim3 & Dong Kyung Chang1 Acid suppressants such as histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are efective in preventing gastrointestinal (GI) bleeding in nonsteroidal anti-infammatory drugs (NSAIDs) users. Despite widespread acid suppressant use, there remain concerns about several potential risks of long-term use. Therefore, we investigated whether gastroprotective agents (GPAs) other than acid suppression therapy are efective in preventing NSAID-related GI injury. To this end, we studied 9,133 patients with osteoarthritis or rheumatoid arthritis who used NSAIDs for ≥1 month. A decrease of 2 g/dL or more in the hemoglobin level was considered a GI injury indicator. The GPAs included acid suppressants and other mucoprotective agents. Acid suppressants included PPIs and H2RAs. Other mucoprotective agents included misoprostol, rebamipide, and eupatilin. During a median follow-up period of 27 (range, 4.3-51.3) weeks, occult GI bleeding occurred in 1,191 (13%) patients. A comparison of patients who used GPAs concomitantly with that of nonusers in a multivariable analysis revealed the hazard ratios (HRs; 95% confdence intervals [CIs]) for occult GI bleeding were 0.30 (0.20-0.44), 0.35 (0.29-0.43), 0.47 (0.23-0.95), 0.43 (0.35-0.51), and 0.98 (0.86-1.12) for PPIs, H2RAs, misoprostol, rebamipide, and eupatilin, respectively. Compared to PPI co-treatment, H2RA, misoprostol, rebamipide, and eupatilin co-treatments were associated with occult GI bleeding HRs (95% CIs) of 1.19 (0.79-1.79), 1.58 (0.72-3.46), 1.44 (0.96-2.16), and 3.25 (2.21-4.77), respectively. Our fndings suggest that mucoprotective agents, such as rebamipide and misoprostol, as well as acid suppressants, are efective in reducing the risk for GI injury in NSAID users. Nonsteroidal anti-infammatory drugs (NSAIDs) are one of the most widely prescribed drugs worldwide because of their analgesic, anti-infammatory, and antipyretic efects. However, despite the various benefts and good efcacy of NSAIDs, their use can lead to mucosal injury of the gastrointestinal (GI) tract including GI bleeding or perforation. Te incidence of clinically signifcant upper GI bleeding in NSAID users has been estimated at 1-2.5/100 person-years1,2. Current evidence suggests that in addition to causing upper GI bleeding, NSAIDs increase the risk of lower GI bleeding to a similar extent as that of upper GI bleeding3–5. 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 2Department of Digital Health, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University School of Medicine, Seoul, South Korea. 3Biostatistics and Clinical Epidemiology Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Correspondence and requests for materials should be addressed to K.K. (email: [email protected]) or D.K.C. (email: dkchang@ skku.edu) SCIENTIFIC REPORTS | (2019) 9:11696 | https://doi.org/10.1038/s41598-019-48173-6 1 www.nature.com/scientificreports/ www.nature.com/scientificreports Total Monotherapy of NSAID plus (N = 9,133) NSAID (N = 2,668) GPA (N = 6,465) P value Age, years 54.2 ± 14.7 55.7 ± 13.6 53.7 ± 15 <0.001 Male 3,145 (34.4) 915 (34.3) 2,230 (34.5) 0.879 BMI (kg/m2) 26.8 ± 4.7 27.7 ± 4.6 26.4 ± 4.5 0.121 Creatinine (mg/dl) 0.7 ± 0.46 0.7 ± 0.5 0.8 ± 0.4 <0.001 Co-morbidity Hypertension 1,133 (12.4) 325 (12.2) 808 (12.5) 0.456 Diabetes mellitus 273 (3) 99 (3.7) 174 (2.7) 0.011 Cerebrovascular disease 103 (1.1) 32 (1.2) 71 (1.1) 0.759 Ischemic heart disease 246 (2.7) 64 (2.4) 182 (2.8) 0.295 Concomitant GPAs None 2,668 (29.2) 2,668 (100) 0 PPI 498 (5.5) 0 498 (7.7) H2RA 1,654 (18.1) 0 1,654 (25.6) Misoprostol 85 (0.9) 0 85 (1.3) Rebamipide 1,509 (16.5) 0 1,509 (23.3) Eupatilin 2,719 (29.8) 0 2,719 (42.1) Table 1. Baseline characteristics of study participants according to GPA use. Values are expressed as means ± standard deviation or percentages. Substantial evidence has indicated that the concomitant use of gastroprotective agents (GPAs) in chronic NSAID users can reduce the risk of upper GI bleeding6,7. Tus, many practice guidelines recommend using GPAs in NSAID users with a high risk of GI bleeding8–10. However, the treatment and prevention of NSAID-associated lower GI bleeding remain unclear and difcult, because the pathogenic mechanisms are diferent and not well understood. GPAs mainly include acid suppressants, such as proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), which primarily have a protective efect against upper GI damage. GPAs other than acid suppressants, including misoprostol, rebamipide, and eupatilin, have a diferent GI tract–protec- tive mechanism. Further, in some studies, misoprostol and rebamipide were reported to be efective against NSAID-associated enteropathy; however, the underlying mechanisms remain unclear11–13. A decrease of ≥2 g/dL in the hemoglobin level has been suggested as a clinically-relevant indicator of GI mucosal damage and has previously been evaluated as an endpoint of GI bleeding in several studies14–18. Tus, a ≥ 2 g/dL drop in the hemoglobin level could be a potential marker for NSAID-induced mucosal damage throughout the GI tract, including both upper and lower GI events. Recently, a prospective study of 84 aspirin users showed that misoprostol was superior to placebo in treat- ing small bowel ulcers complicated by small bowel ulcer bleeding in aspirin users19. Another prospective study of 104 patients who were taking low-dose aspirin or an NSAID, demonstrated that misoprostol was efective for the treatment of small bowel ulcers and erosions20. Further, two prospective studies of 80 patients and 20 patients who were taking NSAIDs reported that rebamipide showed signifcantly higher efcacy than that of pla- cebo in preventing NSAID-induced small bowel mucosal injury11,21. However, to the best of our knowledge, no large-scale study has evaluated the risk for GI bleeding in NSAID users with the concomitant use of a GPA, espe- cially rebamipide or misoprostol. Terefore, we conducted a large cohort study to determine the risk of overall GI bleeding in NSAID users by using diferent GPA co-treatments. Furthermore, we investigated whether GPAs other than PPIs or H2RAs are efective in preventing NSAID-associated occult GI bleeding. Results A total of 6,465 GPA plus NSAID users and 2,668 NSAID users without GPA were included in this study. Te most frequent GPA used was eupatilin (29.8%), followed by H2RAs (18.1%), rebamipide (16.5%), PPI (5.5%), and misoprostol (0.9%). Te mean (standard deviation) age of the 9,133 study participants was 54.2 (14.7) years. Te baseline characteristics of the participants according to concomitant GPA use are shown in Table 1. Te propor- tions of male and female patients were comparable in both groups. Patients without GPA co-treatment were more likely to be older, and to have diabetes and lower levels of creatinine compared to those with GPA co-treatment. Te proportions of comorbidities such as hypertension, cerebrovascular disease, and ischemic heart disease were comparable between both groups. During the median follow-up of 5.7 months (interquartile range, 2.0-9.8 months), occult GI bleeding devel- oped in 1,191 (13%) patients. Of the 1,191 patients with occult bleeding, 82 had endoscopically-confrmed GI bleeding. Sixty-fve patients had upper GI bleeding and 17 had lower GI bleeding. Among those with upper GI bleeding, the most cause of the bleeding was peptic ulcer (54 cases). Lower GI bleeding was noted in seven patients with angiodysplasia, six patients with ulcers, and four patients with diverticular bleeding. Figure 1A shows the Kaplan-Meier curves of the proportion of patients who developed occult GI bleeding during the 12-month study, according to concomitant GPA use. Te incident cases (%) of occult GI bleeding in each group were 703 (10.9%) in the GPA co-treatment group and 488 (18.3%) in the no-GPA co-treatment group (P < 0.001). Te comparison of concomitant GPA users with nonusers by using the multivariable Cox proportional hazard SCIENTIFIC REPORTS | (2019) 9:11696 | https://doi.org/10.1038/s41598-019-48173-6 2 www.nature.com/scientificreports/ www.nature.com/scientificreports Figure 1. (A) Cumulative incidence rate for occult gastrointestinal bleeding between NSAID monotherapy and GPA co-therapy, (B) Cumulative incidence rate for occult gastrointestinal bleeding according to each drug combinations. Multivariable analysis HR 95% CI P value Age, years 1.04 1.03-1.05 <0.001 Male 0.89 0.79-1.02 0.095 BMI (kg/m2) 1.00 1.00-1.01 0.067 Creatinine (mg/dl) 1.01 0.88-1.16 0.877 Co-morbidity Hypertension 1.04 0.87-1.24 0.634 Diabetes mellitus 1.12 0.83-1.51 0.454 Cerebrovascular disease 1.90 1.22-2.97 0.005 Ischemic heart disease 1.61 1.20-2.14 0.001 Concomitant any GPAs use 0.63 0.56-0.71 <0.001 Table 2.
Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
  • What Are the Acute Treatments for Migraine and How Are They Used?

    What Are the Acute Treatments for Migraine and How Are They Used?

    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
  • The Effectiveness of Patches Containing Loxoprofen Sodium

    The Effectiveness of Patches Containing Loxoprofen Sodium

    22 Japanese Journal of Comprehensive Rehabilitation Science (2013) Original Article The effectiveness of patches containing Loxoprofen Sodium Hydrate (LX-P) in the conservative therapy of muscular back pain – Clinical results using the Japanese Orthopaedic Association Back Pain Evaluation Questionnaire (JOABPEQ) Toyoko Asami, MD, PhD,1 Naoya Yamanouchi, MD,1 Akihiko Asami, MD, PhD,2 Hisato Tanaka, MD,3 PhD, Norihiko Nogami, MD, PhD4 1Department of Rehabilitation Medicine, Saga University Hospital, Saga, Japan. 2Saga Social Insurance Hospital, Saga, Japan. 3Tanaka Hospital (Anju Medical Corporation), Saga, Japan. 4Wakakusu Ryoikuen, Tosu, Saga, Japan. ABSTRACT life disability. The rate of effectiveness of LX-P against Asami T, Yamanouchi N, Asami A, Tanaka H, Nogami pain-related disabilities in the fourth week was 62.2%. N. The effectiveness of patches containing Loxoprofen Conclusion: LX-P showed satisfactory analgesic Sodium Hydrate (LX-P) in the conservative therapy of effect and QOL improvement. We believe it is effective muscular back pain - Clinical results using the Japanese for clinical practice. Orthopaedic Association Back Pain Evaluation Keywords: loxoprofen sodium, JOABPEQ, VAS, Questionnaire (JOABPEQ). Jpn J Compr Rehabil Sci QOL, muscular back pain 2013; 4: 22-29. Objectives: We investigated the analgesic effect, Introduction degree of patient satisfaction, and QOL improvement provided by patches containing loxoprofen sodium According to the Ministry of Health, Labour and hydrate (LX-P) using a questionnaire based on the Welfare’s Comprehensive Survey of Living Conditions evaluation criteria of the Japanese Orthopaedic (several surveys conducted in fiscal 2004, 2007, 2010), Association Back Pain Evaluation Questionnaire pain in the locomotive organs, including “lower back (JOABPEQ). pain,” “stiff shoulders,” and “joint pain,” is one of the Methods: In this study of 53 patients (18 men, 35 most common subjective symptoms reported.
  • Ige-Mediated Hypersensitivity to Lysine Clonixinate

    Ige-Mediated Hypersensitivity to Lysine Clonixinate

    67 Practitioner's Corner IgE-Mediated Hypersensitivity to Lysine Clonixinate Villalón García AL, Pérez Pimiento A, López San Martín MG, Iglesias Cadarso A Allergy Department, University Hospital Puerta de Hierro, Madrid, Spain J Investig Allergol Clin Immunol 2021; Vol. 31(1): 67-68 doi: 10.18176/jiaci.0613 Key words: Lysine clonixinate. Drug allergy. Anti-inflammatory analgesics. Urticaria. IgE-mediated hypersensitivity. Palabras clave: Clonixinato de lisina. Alergia a medicamentos. Analgésicos antiinflamatorios. Urticaria. Hipersensibilidad mediada por IgE. Lysine clonixinate belongs to the nicotinic acid family, a family of nonsteroidal anti-inflammatory drugs (NSAIDs), which are in turn a class of antiprostaglandin drugs. At therapeutic doses, it acts mainly by inhibiting cyclooxygenase 2 (COX-2), whereas at lower doses, it inhibits cyclooxygenase 1 (COX-1). It is indicated as an analgesic and anti-inflammatory drug in patients with acute or chronic pain and has proven effective in various algic syndromes such as renal colic, nerve compression, muscular pain, and odontalgia [1]. It is generally administered orally, Figure. Skin prick test. although it is also effective and well tolerated intravenously for the treatment of severe migraine attacks [1-3]. Little is known about cross-reactivity between nicotinic acid family anti-inflammatory drugs (lysine clonixinate, morniflumate, to NSAIDs. Oral challenge with lysine clonixinate was not isonixin, and niflumic acid) in acute allergic reactions. Most performed. Skin prick testing with morniflumate, isonixin, are used as a useful alternative in patients with NSAID niflumic acid, and acetylsalicylic acid dissolved in saline was hypersensitivity [4]. Numerous studies compare the efficacy negative. Oral challenge with acetylsalicylic acid 1 g was well and tolerance profile of oral lysine clonixinate with that of tolerated.
  • Pyridoxine Hydrochloride Pyrrolnitrin Quetiapine Fumarate

    Pyridoxine Hydrochloride Pyrrolnitrin Quetiapine Fumarate

    21822182 Infrared Reference Spectra JP XVII Pyridoxine Hydrochloride Pyrrolnitrin Quetiapine Fumarate The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21832183 Quinapril Hydrochloride Quinine Ethyl Carbonate Quinine Sulfate Hydrate The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21842184 Infrared Reference Spectra JP XVII Rabeprazole Sodium Ranitidine Hydrochloride Rebamipide The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21852185 Reserpine Ribavirin Rifampicin The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21862186 Infrared Reference Spectra JP XVII Risperidone Ritodrine Hydrochloride Rokitamycin The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia.
  • Biological and Pharmaceutical Bulletin Regular Article Association

    Biological and Pharmaceutical Bulletin Regular Article Association

    Biological and Pharmaceutical Bulletin Advance Publication by J-STAGE Advance Publication DOI:10.1248/bpb.b17-00547 November 28, 2017 Biological and Pharmaceutical Bulletin Regular article Association Between Concomitant Use of Acyclovir or Valacyclovir with NSAIDs and an Increased Risk of Acute Kidney Injury:Data Mining of FDA Adverse Event Reporting System Zhihua Yue1, Jinhai Shi2 , Haona Li3 ,Huiyi Li1 1Chinese Pharmacopoeia Commission, Beijing, China 2Tianjin international Joint Academy of Biotechnology & Medicine, Tianjin, China 3Huaihe Hospital of Henan University, Kaifeng, China. Corresponding Author: Zhihua Yue, Ph.D. Chinese Pharmacopoeia Commission, Beijing, China, No.11 Fahua Nanli, Dongcheng District, Beijing,100061, P.R.China E-Mail: [email protected] Ⓒ 2017 The Pharmaceutical Society of Japan SUMMARY NSAIDs are likely to be used concomitantly with acyclovir or valacyclovir in clinical practice, but the study on the safety of such combinations was seldom reported. The objective of the study was to investigate reports of acute kidney injury(AKI) events associated with the concomitant use of oral acyclovir or valacyclovir with an NSAID by using the United States Food and Drug Administration(FDA) Adverse Event Reporting System (AERS) database between January 2004 and June 2012. The frequency of AKI events in patients while simultaneously taking either acyclovir or valacyclovir and an NSAID was compared using the Chi-square test. The effect of concomitant use of acyclovir or valacyclovir and individual NSAIDs on AKI was analyzed by the reporting odds ratio (ROR).The results showed that AKI was reported as the adverse event in 8.6% of the 10,923 patients taking valacyclovir compared with 8.7% of the 2,556 patients taking acyclovir (p=NS).However, AKI was significantly more frequently reported in patients simultaneously taking valacyclovir and an NSAID(19.4%)than in patients simultaneously taking acyclovir and an NSAID(10.5%)(p<0.01).
  • Pharmaceuticals and Medical Devices Safety Information No

    Pharmaceuticals and Medical Devices Safety Information No

    Pharmaceuticals and Medical Devices Safety Information No. 264 December 2009 Table of Contents 1. Safety measures for anaphylaxis and anaphylactoid symptoms associated with injectable antibiotics ............................................... 4 2. Important Safety Information .................................................................. 7 .1. Salazosulfapyridine ···················································································· 7 .2. Pethidine hydrochloride, pethidine hydrochloride/levallorphan tartrate ··················· 9 3. Revision of PRECAUTIONS (No. 211) Indometacin (oral dosage form) (and 7 others) ...........................................................13 4. List of products subject to Early Post-marketing Phase Vigilance ............................................... 15 This Pharmaceuticals and Medical Devices Safety Information (PMDSI) is issued based on safety information collected by the Ministry of Health, Labour and Welfare. It is intended to facilitate safer use of pharmaceuticals and medical devices by healthcare providers. PMDSI is available on the Pharmaceuticals and Medical Devices Agency website (http://www.pmda.go.jp/english/index.html) and on the MHLW website (http://www.mhlw.go.jp/, Japanese only). Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Pharmaceutical and Food Safety Bureau, Office of Safety I, Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency 1-2-2
  • S1 Table. List of Medications Analyzed in Present Study Drug

    S1 Table. List of Medications Analyzed in Present Study Drug

    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
  • GP093 ID#2490.Pdf

    GP093 ID#2490.Pdf

    Comparison of the effectiveness of four major drugs prescribed for chronic low back pain in Japan ーNationwide multicenter study Gen Inoue, Takashi Kaito, Yukihiro Matsuyama, Toshihiko Yamashita Mamoru Kawakami, Kazuhisa Takahashi, Munehito Yoshida Shiro Imagama, Seiji Ohtori, Toshihiko Taguchi, Hirotaka Haro Hiroshi Taneichi, Masashi Yamazaki, Kotaro Nishida, Hiroshi Yamada Daijiro Kabata, Ayumi Shintani, Motoki Iwasaki, Manabu Ito Naohisa Miyakoshi, Hideki Murakami, Kazuo Yonenobu Tomoyuki Takura, Joji Mochida The Project Committee of the Japanese Society for Spine Surgery and Related Research (JSSR) Disclosures The authors have nothing to disclose. Purpose To compare the effectiveness of acetaminophen, celecoxib, loxoprofen, and the tramadol / acetaminophen combination drug (T+A CD) using several outcome measures, and to establish evidence of the optimal pharmacological treatment option for cLBP. Project research of JSSR • Started in 2014 as Japanese nationwide multicenter study to examine the cost-effectiveness of drug therapy for cLBP • Subjects are patients with cLBP treated with four major drugs, loxoprofen, celecoxib, acetaminophen, and T+A CD used for cLBP in Japan • Total 602 patients were included from January 2014 to June 2016, and prospectively analyzed for 6 months. Materials and Methods Patients who were treated with one of the major drugs for cLBP in Japan, Acetaminophen, Celecoxib, Loxoprofen, or tramadol / acetaminophen combination drug (T+A CD). Inclusion cliteria n=471 (male: 269, female: 202) Ø LBP lasting for ≥ 3
  • Anti-Inflammatory Analgesic Plaster Entzundungshemmendes, Analgetisches Pflaster Sparadrap Analgesique Anti-Inflammatoire

    Anti-Inflammatory Analgesic Plaster Entzundungshemmendes, Analgetisches Pflaster Sparadrap Analgesique Anti-Inflammatoire

    _ <v Europaisches 111111111111111111111111111111111 JGV/l Eur°Pean Patent Office <*S Office europeen des brevets (11) EP 0 607 434 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) int. CI.6: A61 K 31/19, A61K31/215, of the grant of the patent: A61 K 9/70, A61K31/40 27.01.1999 Bulletin 1999/04 (86) International application number: ..... - ...number: 92916806.0 (21) Application PCT/JP92/01022 (22) Date of filing: 10.08.1992 x 7 3 (87) International. 4 4..... publication 4. number: WO 93/04677 (18.03.1993 Gazette 1993/08) (54) ANTI-INFLAMMATORY ANALGESIC PLASTER ENTZUNDUNGSHEMMENDES, ANALGETISCHES PFLASTER SPARADRAP ANALGESIQUE ANTI-INFLAMMATOIRE (84) Designated Contracting States: • TATEISHI, Tetsuro, AT BE CH DE FR GB IE IT LI LU NL SE Hisamitsu Pharmaceutical Co Inc Tosu-shi, Saga 841 (JP) (30) Priority: 30.08.1991 J P 246665/91 (74) Representative: (43) Date of publication of application: Bond, Bentley George 27.07.1994 Bulletin 1994/30 Haseltine Lake & Co., Imperial House, (73) Proprietor: 15-19 Kingsway HISAMITSU PHARMACEUTICAL CO. INC. London WC2B 6UD (GB) Tosu-shi Saga 841 (JP) (56) References cited: (72) Inventors: JP-A- 1 040 420 JP-A-55133 310 • NAKAGAWA, Akira, JP-A-56 020 515 JP-A-59 227 819 Hisamitsu Pharmaceutical Co. Inc. JP-A-60152 413 JP-A-63 246 327 Tosu-shi, Saga 841 (JP) • HIRANO, Munehiko, CHEMICAL ABSTRACTS, vol. 109, no. 12, 19 Hisamitsu Pharmaceutical Co Inc. September 1988, Columbus, Ohio, US; abstract Tosu-shi, Saga 841 (JP) no. 98839x, & JP-A-62 240 612 (HISAMITSU PHARMACEUTICAL CO.,INC.) 21 October 1987 CO CO o Note: Within nine months from the publication of the mention of the grant of the European patent, give CO any person may notice to the European Patent Office of opposition to the European patent granted.
  • Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3 S

    Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3 S

    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2016/07/27/dmd.116.070722.DC1 1521-009X/44/10/1543–1549$25.00 http://dx.doi.org/10.1124/dmd.116.070722 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:1543–1549, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3 s Kenji Ikemura, Yugo Hamada, Chinatsu Kaya, Tomoyuki Enokiya, Yuichi Muraki, Hiroki Nakahara, Hajime Fujimoto, Tetsu Kobayashi, Takuya Iwamoto, and Masahiro Okuda Department of Clinical Pharmacy and Biopharmaceutics, Mie University Graduate School of Medicine, Tsu (K.I., Y.H., T.I., M.O.); Department of Pharmacy, Mie University Hospital, Tsu (K.I., T.E., Y.M., T.I., M.O.); Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka (C.K.); Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Tsu (H.N., H.F., T.K.), Mie, Japan Received March 30, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Pemetrexed, a multitargeted antifolate, is eliminated by tubular effect of lansoprazole was much greater than those of other PPIs secretion via human organic anion transporter 3 (hOAT3). Although and the apparent IC50 value of lansoprazole against pemetrexed proton pump inhibitors (PPIs) are frequently used in cancer patients, transport via hOAT3 was 0.57 6 0.17 mM. The inhibitory type of the drug interaction between PPIs and pemetrexed remains to be lansoprazole was competitive. In a retrospective study, multivariate clarified.